Dcy636

Phase 1

Novartis

Dcy636 is one of 4 therapeutic programs targeting Dermatitis, Atopic. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dermatitis, AtopicRecruiting

Dermatitis, AtopicPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

Amlitelimab

Sanofi

Phase 3

7 2

Calcineurin Inhibitors

Sanofi

Preclinical

2 3

Dcy636

Novartis

Phase 1

1 4

Oral Corticosteroids

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Dermatitis, Atopic

NCT07604324

Clinical

Trials by Indication[1]

Dermatitis, Atopic1 trial

A Two-part, Randomized, Participant- and Investigator-blinded, Placebo Controlled First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of DCY636 in a Single Ascending Dose Part in Healthy Participants and in a Multiple Dose Part in Participants With Moderate to Severe Atopic Dermatitis

Recruiting· Novartis logo

Novartis·Phase 1·NCT07604324·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dcy636. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dcy636. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novartis

Dcy636

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Dermatitis, Atopic1 trial

References

Drug Info

Quick Facts

Related News